Becton Dickinson and (BDX) Rating Lowered to Hold at Zacks Investment Research

Becton Dickinson and (NYSE:BDX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.

According to Zacks, “In the last year, Becton, Dickinson and Company, popularly known as BD, has outperformed the broader industry. BD recently completed the acquisition of C. R. Bard. The company will establish a new segment — BD Interventional in which Bard will be integrated. The acquisition is viewed as a strategic one which will generate benefits from complementary businesses and geographical expansion. In recent past, BD announced that it will divest its soft tissue core needle biopsy products for $100 million to Merit Medical. On the flip side, lackluster performance by the Medical segment, from the prior year period is a concern. Performance in the segment was affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the United States. BD temporarily paused shipments of its insulin infusion sets. The voluntary recall of Barricor blood collection tubes in the recent past also adds to our woes.”

Other equities analysts have also recently issued research reports about the company. Deutsche Bank set a $260.00 price target on Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. Argus upped their price target on Becton Dickinson and to $235.00 and gave the company a “buy” rating in a report on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 price target on shares of Becton Dickinson and in a report on Friday, November 3rd. Morgan Stanley upped their price target on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $210.00 price target on shares of Becton Dickinson and in a report on Wednesday, October 25th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $230.20.

Becton Dickinson and (NYSE BDX) opened at $227.71 on Friday. Becton Dickinson and has a 12-month low of $169.19 and a 12-month high of $229.68. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The firm has a market capitalization of $52,240.00, a PE ratio of 48.97, a P/E/G ratio of 1.76 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the previous year, the firm earned $2.12 EPS. The firm’s revenue was down 2.0% compared to the same quarter last year. analysts forecast that Becton Dickinson and will post 10.66 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Family Firm Inc. raised its holdings in shares of Becton Dickinson and by 0.5% in the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 6 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its holdings in shares of Becton Dickinson and by 0.4% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after buying an additional 6 shares in the last quarter. NBT Bank N A NY raised its holdings in shares of Becton Dickinson and by 0.3% in the 2nd quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock worth $654,000 after buying an additional 10 shares in the last quarter. Good Life Advisors LLC raised its holdings in shares of Becton Dickinson and by 0.6% in the 2nd quarter. Good Life Advisors LLC now owns 2,494 shares of the medical instruments supplier’s stock worth $491,000 after buying an additional 14 shares in the last quarter. Finally, Pathstone Family Office LLC raised its holdings in shares of Becton Dickinson and by 0.4% in the 2nd quarter. Pathstone Family Office LLC now owns 3,974 shares of the medical instruments supplier’s stock worth $2,530,000 after buying an additional 15 shares in the last quarter. 75.53% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and (BDX) Rating Lowered to Hold at Zacks Investment Research” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/14/becton-dickinson-and-bdx-rating-lowered-to-hold-at-zacks-investment-research.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply